Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Operations: 2012-2024

Historic Cash from Operations for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to -$40.7 million.

  • Akebia Therapeutics' Cash from Operations rose 519.79% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 184.15%. This contributed to the annual value of -$40.7 million for FY2024, which is 73.88% down from last year.
  • Akebia Therapeutics' Cash from Operations amounted to -$40.7 million in FY2024, which was down 73.88% from -$23.4 million recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Cash from Operations peaked at -$23.4 million during FY2023, and registered a low of -$253.0 million during FY2021.
  • Its 3-year average for Cash from Operations is -$45.7 million, with a median of -$40.7 million in 2024.
  • As far as peak fluctuations go, Akebia Therapeutics' Cash from Operations tumbled by 129.16% in 2021, and later surged by 71.08% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Cash from Operations (MRY) stood at -$110.4 million in 2020, then tumbled by 129.16% to -$253.0 million in 2021, then soared by 71.08% to -$73.2 million in 2022, then skyrocketed by 68.03% to -$23.4 million in 2023, then tumbled by 73.88% to -$40.7 million in 2024.
  • Its Cash from Operations was -$40.7 million in FY2024, compared to -$23.4 million in FY2023 and -$73.2 million in FY2022.